News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News CVD Hospitalization in Older Adults Higher in US Than in Denmark Michael O'Riordan February 07, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025
News Features Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s? Michael O'Riordan January 17, 2025
News Conference News AHA 2024 GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes Michael O'Riordan November 17, 2024
News Conference News AHA 2024 Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD Yael L. Maxwell November 16, 2024
News Daily News Rural Counties Bore Brunt of Worsening CV Mortality During Pandemic Yael L. Maxwell November 15, 2024
News Daily News Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key Todd Neale November 13, 2024
News Daily News Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data Michael O'Riordan November 07, 2024
News Features Can ‘Body Roundness Index’ Replace BMI? That Depends, Say Experts Michael O'Riordan October 21, 2024
News Daily News Time-Restricted Eating Tightens Glycemic Control in Patients With Metabolic Syndrome Caitlin E. Cox October 04, 2024
News Conference News HFSA 2024 Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity Todd Neale October 01, 2024
News Daily News Medicaid Coverage Improves CV Risk in Some, Post Hoc Analysis Shows Todd Neale September 25, 2024
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News ESC 2024 Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery Todd Neale August 30, 2024